Quintiles Names Tom Pike CEO
Quintiles announced the appointment of Tom Pike as Chief Executive Officer. This appointment is part of the company’s long-term succession planning. Dennis Gillings, CBE, who founded the company, continues as Executive Chairman of its Board of Directors. Pike joins Quintiles on April 30, 2012.
“Tom has an impressive track record of helping customers navigate fast-changing environments and solving complex business issues,” Gillings said. “He has experience with organizations our size and much larger that will be extremely valuable to us. Tom has a disciplined and forthright approach that will enable him to earn the trust of customers and employees alike. I’m confident he will soon make his mark on our company and the industry at large, continuing the Quintiles tradition of entrepreneurial leadership and pioneering growth.”
Pike brings 30 years of experience to Quintiles, spanning a variety of industries and leading companies. He spent 22 years at Accenture, including more than 10 years in leadership roles. At Accenture, Pike’s roles included leading the North America Health and Products business areas. Prior to that, he was the global chief operating officer for Accenture’s Resources operating group and had also served as the company’s chief strategy officer. Since leaving Accenture in 2010, Pike has been involved with a number of start-ups in the technology and healthcare sectors.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
